Brief: Essa Pharma Announces First Patient Dosed In A Phase 1/2 Clinical Trial Of EPI-7386
19/01/2022 12:35
Jan 19 (Reuters) - ESSA Pharma Inc EPIX.O :
* ESSA PHARMA ANNOUNCES FIRST PATIENT DOSED IN A PHASE 1/2
CLINICAL TRIAL OF EPI-7386 IN COMBINATION WITH ENZALUTAMIDE IN
PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Source text for Eikon: ID:nCNWZmld6a
Further company coverage: EPIX.O
Recent news on ESSA Pharma
See all newsBrief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: Essa Securityholders Approve Acquisition By Xenotherapeutics
Brief: ESSA Pharma Provides Update On Its Application To The Supreme Court Of British Columbia For Amended Interim Order
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics
Brief: ESSA Pharma Amends Agreement with XenoTherapeutics